NO20084688L - lmidazo[4,5-b]pyridin-2-on og oksazol[4,5-b]pyridin-2-onforbindelser og analoger derav cancerterapeutiske forbindelser - Google Patents
lmidazo[4,5-b]pyridin-2-on og oksazol[4,5-b]pyridin-2-onforbindelser og analoger derav cancerterapeutiske forbindelserInfo
- Publication number
- NO20084688L NO20084688L NO20084688A NO20084688A NO20084688L NO 20084688 L NO20084688 L NO 20084688L NO 20084688 A NO20084688 A NO 20084688A NO 20084688 A NO20084688 A NO 20084688A NO 20084688 L NO20084688 L NO 20084688L
- Authority
- NO
- Norway
- Prior art keywords
- independently
- linker
- compounds
- raf
- pyridin
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- JXXWJMUPNZDILL-UHFFFAOYSA-N imidazo[4,5-b]pyridin-2-one Chemical compound C1=CC=NC2=NC(=O)N=C21 JXXWJMUPNZDILL-UHFFFAOYSA-N 0.000 title abstract 2
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 title 1
- 239000012830 cancer therapeutic Substances 0.000 title 1
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical class OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 title 1
- 125000005647 linker group Chemical group 0.000 abstract 10
- 125000001424 substituent group Chemical group 0.000 abstract 4
- 230000000694 effects Effects 0.000 abstract 3
- 102000027426 receptor tyrosine kinases Human genes 0.000 abstract 3
- 108091008598 receptor tyrosine kinases Proteins 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 102000018471 Proto-Oncogene Proteins B-raf Human genes 0.000 abstract 2
- 108010091528 Proto-Oncogene Proteins B-raf Proteins 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 230000004663 cell proliferation Effects 0.000 abstract 2
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 150000001408 amides Chemical class 0.000 abstract 1
- 125000005488 carboaryl group Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 150000002170 ethers Chemical class 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- OVLXOTUWFLHWQT-UHFFFAOYSA-N oxazolo[4,5-b]pyridin-2(3H)-one Chemical class C1=CC=C2OC(=O)NC2=N1 OVLXOTUWFLHWQT-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US74563306P | 2006-04-26 | 2006-04-26 | |
GBGB0608268.9A GB0608268D0 (en) | 2006-04-26 | 2006-04-26 | Therapeutic compounds |
PCT/GB2007/001534 WO2007125330A1 (fr) | 2006-04-26 | 2007-04-26 | Composés d'imidazo[4,5-b]pyridin-2-one et d'oxazolo[4,5- b]pyridin-2-one et leurs analogues en tant que composés de traitement du cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20084688L true NO20084688L (no) | 2009-01-26 |
Family
ID=38421488
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20084688A NO20084688L (no) | 2006-04-26 | 2008-11-06 | lmidazo[4,5-b]pyridin-2-on og oksazol[4,5-b]pyridin-2-onforbindelser og analoger derav cancerterapeutiske forbindelser |
Country Status (7)
Country | Link |
---|---|
US (1) | US7951819B2 (fr) |
EP (1) | EP2013207B1 (fr) |
JP (1) | JP2009534457A (fr) |
AU (1) | AU2007245495A1 (fr) |
CA (1) | CA2649994A1 (fr) |
NO (1) | NO20084688L (fr) |
WO (1) | WO2007125330A1 (fr) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110158944A1 (en) * | 2007-11-30 | 2011-06-30 | Hosted Thomas J | Braf biomarkers |
US8198279B2 (en) | 2007-12-19 | 2012-06-12 | Institute Of Cancer Research: Royal Cancer Hospital (The) | Pyrido[2,3-b]pyrazin-8-substituted compounds and their use |
GB0807609D0 (en) | 2008-04-25 | 2008-06-04 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
US9229008B2 (en) | 2008-08-19 | 2016-01-05 | Merck Sharp & Dohme Corp. | IL-8 level as a determinant of responsivity of a cancer to treatment |
WO2011021678A1 (fr) * | 2009-08-21 | 2011-02-24 | 武田薬品工業株式会社 | Composé à hétérocycles fusionnés |
PL2531502T3 (pl) * | 2010-02-01 | 2014-08-29 | Cancer Research Tech Ltd | 1-(5-tert-Butylo-2-fenylo-2H-pirazol-3-ilo)-3-[2-fluoro-4-(1-metylo-2-okso-2,3-dihydro-1H-imidazo[4,5-b]pirydyn-7-yloksy)-fenylo]-mocznik i związki pokrewne oraz ich zastosowanie w terapii |
US9131874B2 (en) | 2010-04-21 | 2015-09-15 | The Regents Of The University Of Michigan | Fluoroscopy-independent, endovascular aortic occlusion system |
KR20140038382A (ko) | 2011-03-10 | 2014-03-28 | 프로벡투스 파마슈티컬스 인코포레이티드 | 암의 치료 증대를 위한 국소 면역조절 치료제와 전신 면역조절 치료제의 복합제 |
WO2013022766A1 (fr) * | 2011-08-05 | 2013-02-14 | Flynn Gary A | Préparation et procédés d'utilisation d'ortho-aryle hétéroaryle à 5 chaînons -carboxamide contenant des inhibiteurs de kinases multicibles |
US9474882B2 (en) | 2013-02-26 | 2016-10-25 | Prytime Medical Devices, Inc. | Fluoroscopy-independent balloon guided occlusion catheter and methods |
EP3043858B1 (fr) | 2013-09-09 | 2022-11-02 | Prytime Medical Devices, Inc. | Cathéter d'occlusion au profil bas |
GB201320732D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Methods of chemical synthesis |
GB201320729D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
CA2941438C (fr) | 2014-06-10 | 2018-04-10 | Prytime Medical Devices, Inc. | Pointe de guidage dans un passage |
WO2016149653A2 (fr) | 2015-03-19 | 2016-09-22 | Prytime Medical Devices, Inc. | Système et procédé pour cathéter d'occlusion à ballonnet à faible encombrement |
CA2990479C (fr) | 2016-06-02 | 2019-03-26 | Prytime Medical Devices, Inc. | Systeme de catheter d'occlusion comprenant un catheter de gonflage et un ballonnet d'occlusion |
EP3500569B1 (fr) * | 2016-08-16 | 2022-05-18 | Merck Patent GmbH | 2-oxo-imidazopyridines en tant qu'inhibiteurs réversibles de btk et leurs utilisations |
CN110446523B (zh) | 2017-01-12 | 2022-06-10 | 加利福尼亚大学董事会 | 用于重症护理的血管内灌流增强 |
EP3612086A4 (fr) | 2017-04-21 | 2021-01-20 | The Regents of the University of California, A California Corporation | Débitmètre aortique et pompe pour occlusion aortique partielle |
BR112020015581A2 (pt) | 2018-01-31 | 2021-02-02 | Deciphera Pharmaceuticals, Llc | terapia de combinação para o tratamento de tumores estromais gastrointestinais |
CA3149846A1 (fr) | 2019-08-08 | 2021-02-11 | B.C.I. Pharma | Derives d'isoquinoline utilises comme inhibiteurs de proteine kinase |
MX2022001863A (es) | 2019-08-12 | 2022-05-30 | Deciphera Pharmaceuticals Llc | Metodos para tratar los tumores del estroma gastrointestinal. |
WO2021030405A1 (fr) | 2019-08-12 | 2021-02-18 | Deciphera Pharmaceuticals, Llc | Ripretinib pour le traitement de tumeurs stromales gastro-intestinales |
WO2021057696A1 (fr) * | 2019-09-27 | 2021-04-01 | 隆泰申医药科技(南京)有限公司 | Composé hétéroaryle et ses applications |
EP4084779A1 (fr) | 2019-12-30 | 2022-11-09 | Deciphera Pharmaceuticals, LLC | Compositions de 1-(4-bromo-5-(1-éthyl-7-(méthylamino)-2-oxo-1,2-dihydro -1,6-naphthyridine-3-yl)-2-fluorophényl)-3-phényluree |
AU2020419197B2 (en) | 2019-12-30 | 2023-08-31 | Deciphera Pharmaceuticals, Llc | Amorphous kinase inhibitor formulations and methods of use thereof |
JP2023519191A (ja) | 2020-03-16 | 2023-05-10 | サータス クリティカル ケア, インコーポレイテッド | 血流制御デバイス、システム、及び方法、並びにそれらのエラー検出 |
US11629143B2 (en) | 2020-10-01 | 2023-04-18 | Vibliome Therapeutics, Llc | HipK4 inhibitors and uses thereof |
TWI812301B (zh) * | 2021-06-24 | 2023-08-11 | 南韓商Lg化學股份有限公司 | 作為ron抑制劑之新穎尿素衍生物化合物 |
US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5665863A (en) | 1979-10-31 | 1981-06-03 | Tokyo Organ Chem Ind Ltd | Novel aniline derivative, its preparation and pesticide containing the same |
JPS5738777A (en) | 1980-08-19 | 1982-03-03 | Sogo Yatsukou Kk | 2-sufanilamidopyrathyn derivative |
US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
US5879672A (en) | 1994-10-07 | 1999-03-09 | Regeneron Pharmaceuticals, Inc. | Tie-2 ligand 1 |
US5643755A (en) | 1994-10-07 | 1997-07-01 | Regeneron Pharmaceuticals Inc. | Nucleic acid encoding tie-2 ligand |
JPH10506011A (ja) | 1994-09-22 | 1998-06-16 | ヘルシンキ、ユニバーシティ、ライセンシング、リミテッド、オサケ、ユキチュア | レセプターチロシンキナーゼ、tieのプロモーター |
CA2262403C (fr) | 1995-07-31 | 2011-09-20 | Urocor, Inc. | Biomarqueurs et cibles de diagnostic, de pronostic et de traitement du cancer de la prostate |
US6218529B1 (en) | 1995-07-31 | 2001-04-17 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer |
ZA971896B (en) | 1996-03-26 | 1998-09-07 | Du Pont Merck Pharma | Aryloxy-and arythio-fused pyridines and pyrimidines and derivatives |
US6030831A (en) | 1997-09-19 | 2000-02-29 | Genetech, Inc. | Tie ligand homologues |
EP1017384B1 (fr) | 1997-09-26 | 2004-11-10 | Zentaris GmbH | Composes a base d'azabenzimidazole destines a la modulation d'une fonction de proteine kinase de serine/threonine |
GB9721437D0 (en) | 1997-10-10 | 1997-12-10 | Glaxo Group Ltd | Heteroaromatic compounds and their use in medicine |
GB2356398A (en) | 1999-11-18 | 2001-05-23 | Lilly Dev Ct S A | Preparation of arylsulfamides |
DE60021423T2 (de) | 1999-12-21 | 2006-04-13 | Sugen, Inc., San Diego | 4-substituierte 7-aza-indolin-2-one und ihre verwendung als proteinkinaseinhibitoren |
US6492529B1 (en) | 2000-01-18 | 2002-12-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | Bis pyrazole-1H-pyrazole intermediates and their synthesis |
EP1341771A2 (fr) * | 2000-11-29 | 2003-09-10 | Glaxo Group Limited | Composes chimiques |
AU2002353228B2 (en) | 2001-12-21 | 2008-09-11 | The Welcome Trust | Genes |
WO2004014300A2 (fr) | 2002-08-09 | 2004-02-19 | Merck & Co., Inc. | Inhibiteurs de la tyrosine kinase |
TW200616974A (en) | 2004-07-01 | 2006-06-01 | Astrazeneca Ab | Chemical compounds |
CA2577275A1 (fr) | 2004-08-31 | 2006-03-09 | Astrazeneca Ab | Derives de quinazolinone et utilisation de ces derives en tant qu'inhibiteurs du b-raf |
GB0423554D0 (en) | 2004-10-22 | 2004-11-24 | Cancer Rec Tech Ltd | Therapeutic compounds |
-
2007
- 2007-04-26 AU AU2007245495A patent/AU2007245495A1/en not_active Abandoned
- 2007-04-26 CA CA002649994A patent/CA2649994A1/fr not_active Abandoned
- 2007-04-26 WO PCT/GB2007/001534 patent/WO2007125330A1/fr active Application Filing
- 2007-04-26 US US12/298,325 patent/US7951819B2/en not_active Expired - Fee Related
- 2007-04-26 EP EP07732571A patent/EP2013207B1/fr active Active
- 2007-04-26 JP JP2009507165A patent/JP2009534457A/ja active Pending
-
2008
- 2008-11-06 NO NO20084688A patent/NO20084688L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CA2649994A1 (fr) | 2007-11-08 |
US20090325945A1 (en) | 2009-12-31 |
US7951819B2 (en) | 2011-05-31 |
JP2009534457A (ja) | 2009-09-24 |
WO2007125330A1 (fr) | 2007-11-08 |
AU2007245495A1 (en) | 2007-11-08 |
EP2013207B1 (fr) | 2012-04-25 |
EP2013207A1 (fr) | 2009-01-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20084688L (no) | lmidazo[4,5-b]pyridin-2-on og oksazol[4,5-b]pyridin-2-onforbindelser og analoger derav cancerterapeutiske forbindelser | |
NO20072546L (no) | Imidazo[4,5-b]pyridin-2-on og oksazolo[4,5-B]pyridin-2-on forbindelser og analoger derav som terapeutiske forbindelser | |
CN109069504B (zh) | 氨基噻唑化合物及其用途 | |
ES2517690T3 (es) | Quinazolinona, quinolona y análogos relacionados como moduladores de sirtuina | |
ES2252512T3 (es) | Combinaciones antineoplasticas. | |
WO2006067466A3 (fr) | Pyrazines, pyridines et leurs derives, utilises comme composes therapeutiques | |
JP2023065403A (ja) | 大環式化合物およびその使用 | |
JP2020514409A (ja) | ジアリール大環状化合物を含む併用療法 | |
KR20150023223A (ko) | Cdk8/cdk19 선택성 억제제 및 암에 대한 항-전이 및 화학예방 방법에서 이들의 용도 | |
NO20074274L (no) | Tetrahydroindolon og tetrahydroindazolonderivater | |
US11365189B2 (en) | Heterocyclic inhibitors of tyrosine kinase | |
AU2013341271A1 (en) | Combination therapy | |
NO20063768L (no) | 1H-tieno[2,3c] pyrazolderivater anvendelige som kinaseinhibitorer | |
BRPI0614456B1 (pt) | 8-metoxi-9h-isotiazol[5,4-b]quinolina-3,4-dionas e compostos relacionados como agentes antiinfecciosos | |
US10370400B2 (en) | 4-methylumbelliferone derivatives for treatment for immune modulation | |
NO20092035L (no) | Tiazolylforbindelser anvendbare som kinaseinhibitorer | |
KR101532242B1 (ko) | 흑색종의 치료 | |
JP2010535211A (ja) | 炎症性障害、脱髄障害および癌を治療するためのインダゾール化合物 | |
EP2464642A1 (fr) | Procédé de promotion de l'apoptose et d'inhibition de la métastase | |
CA2847091A1 (fr) | Compositions et methodes utilisables en vue du traitement du cancer et faisant appel a un inhibiteur de pi3k.beta. et a un inhibiteur de la voie mapk, dont, notamment, les inhibiteurs ciblant mek et raf | |
Hei et al. | Alkylsulfonamide-containing quinazoline derivatives as potent and orally bioavailable PI3Ks inhibitors | |
CN109071462A (zh) | 喹唑啉衍生物或其盐和包含其的药物组合物 | |
CN117643587A (zh) | 用于治疗癌症的杂二环羧酸 | |
EP3421039B1 (fr) | Médicament pour le traitement du cancer caractérisé par l'administration d'une association d'un inhibiteur de l'axl et d'un inhibiteur de point de contrôle immunitaire | |
WO2018177865A1 (fr) | Composés destinés à être utilisés comme inhibiteurs d'héparanase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |